<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Side effects of androgen deprivation therapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Side effects of androgen deprivation therapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Side effects of androgen deprivation therapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Matthew R Smith, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            W Robert Lee, MD, MS, MEd
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerome P Richie, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 20, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Androgen deprivation therapy (ADT) is the main therapeutic approach for males with metastatic prostate cancer. ADT is also frequently used in patients whose only manifestation of disseminated disease is a rising or elevated serum prostate-specific antigen and in the setting of adjuvant or neoadjuvant therapy in conjunction with initial treatment of males with intermediate- or high-risk prostate cancer. (See
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6947.html" rel="external">
          "Initial management of regionally localized intermediate-, high-, and very high-risk prostate cancer and those with clinical lymph node involvement"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6933.html" rel="external">
          "Role of systemic therapy in patients with a biochemical recurrence after treatment for localized prostate cancer"
         </a>
         .)
        </p>
        <p>
         Despite the potential benefits associated with its use, ADT can cause a range of side effects that negatively affect quality of life and may necessitate a change in therapy. Many of these side effects also occur with alternative hormone therapy strategies that target androgen signaling pathways (ie, androgen receptor pathway inhibitors, including
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         ,
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">
          apalutamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">
          darolutamide
         </a>
         ), although less is known about their adverse effects [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway"
         </a>
         .)
        </p>
        <p>
         The side effects of hormone therapy for prostate cancer, their prevention and management, and the potential role of an alternative hormonal strategy are discussed here.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          SEXUAL DYSFUNCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vast majority of males receiving continuous ADT who are potent prior to therapy develop sexual dysfunction. Loss of libido in males receiving gonadotropin-releasing hormone (GnRH) agonists usually develops within the first several months, and erectile dysfunction follows [
         <a href="#rid3">
          3
         </a>
         ]. While the majority of males report diminution or total lack of sex drive on ADT, it is not universal. In addition, studies have shown that sexual activity is not solely driven by libido and that libido can be maintained while on ADT [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Sexual dysfunction should be anticipated and couples counseled before ADT is started. Sex therapists may be helpful in managing these issues once they become problematic. (See
         <a class="medical medical_review" href="/z/d/html/100080.html" rel="external">
          "Overview of sexual dysfunction in male cancer survivors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">
          "Treatment of male sexual dysfunction"
         </a>
         .)
        </p>
        <p>
         Recovery of erectile function is possible after discontinuation of short-term ADT (eg, in males who receive neoadjuvant and adjuvant ADT with radiation therapy for high-risk localized or locally advanced disease) [
         <a href="#rid3">
          3
         </a>
         ]. However, it may be delayed and incomplete.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          OSTEOPOROSIS AND BONE FRACTURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         ADT increases bone turnover, decreases bone mineral density, and increases the risk of bone fractures in males with prostate cancer [
         <a href="#rid5">
          5
         </a>
         ]. Loss of bone mineral density can be detected after six to nine months of ADT, and longer therapy confers a higher risk [
         <a href="#rid6">
          6-9
         </a>
         ]. Osteoporotic skeletal fractures occur in up to 20 percent of males within five years of starting ADT [
         <a href="#rid6">
          6,10
         </a>
         ].
        </p>
        <p>
         Other factors contributing to osteoporosis can include reduced intake of calcium, low vitamin D levels, alcohol abuse, smoking, and chronic use of corticosteroids. (See
         <a class="medical medical_review" href="/z/d/html/2049.html" rel="external">
          "Etiology of osteoporosis in men"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Assessment of bone density
         </span>
         <span class="headingEndMark">
          —
         </span>
         We obtain a baseline assessment of bone density in all males who will be treated with long-term ADT (ie, ≥18 months).
        </p>
        <p>
         Baseline measurement of bone density is appropriate in males who will be treated with ADT, although guidelines differ as to whether the recommendation should be influenced by ADT duration. As an example, consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) [
         <a href="#rid11">
          11
         </a>
         ] and American Society of Clinical Oncology (ASCO) [
         <a href="#rid12">
          12,13
         </a>
         ] recommend a baseline assessment via dual x-ray absorptiometry (DXA) at initiation of ADT treatment without specifying a minimum duration, while other expert guidelines suggest screening only for those receiving long-term (≥18 months) ADT [
         <a href="#rid14">
          14
         </a>
         ]. Regardless, the available data suggest that although prior DXA screening is associated with a modestly decreased risk of future fractures in males receiving ADT, fewer than 10 percent of patients initiating ADT for localized or regional prostate cancer undergo a baseline DXA scan [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         After the initial baseline study, retesting is based upon clinical judgment, and usually recommended at least every two years [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Although the diagnosis of osteoporosis in males is typically accomplished using a DXA scan, at least some data suggest that conventional DXA measurement of bone density may not provide an adequate assessment of fracture risk in males with prostate cancer on ADT [
         <a href="#rid16">
          16,17
         </a>
         ]. Results may be better with quantitative CT, the indications for which are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Preventive strategies
         </span>
        </p>
        <p class="headingAnchor" id="H261290808">
         <span class="h3">
          Lifestyle modification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Beneficial lifestyle modifications include smoking cessation, moderating alcohol and caffeine consumption, vitamin D and calcium supplementation, and regular weight bearing or resistance exercises. (See
         <a class="local">
          'Role of structured exercise'
         </a>
         below.)
        </p>
        <p>
         Consistent with guidelines from ASCO, we recommend dietary calcium intake (food and supplements) of 1000 to 1200 mg daily and supplemental vitamin D of 800 to 1000 international units daily for all males receiving ADT [
         <a href="#rid12">
          12
         </a>
         ]. We also recommend weight bearing exercise, decreased alcohol consumption, and smoking cessation [
         <a href="#rid18">
          18-21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2165880127">
         <span class="h3">
          Osteoclast inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For males without bone metastases who are treated with long-term (&gt;6 month) ADT, an osteoclast inhibitor such as a bisphosphonate or
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         can decrease bone turnover and increase bone mineral density. We suggest an osteoclast inhibitor to reduce the risk of fracture in the setting of osteoporosis (T scores of -2.5 or less in the femoral neck, total hip, or lumbar spine), or when the 10-year probability of hip fracture (using the FRAX algorithm or a different tool) is ≥3 percent or the 10-year probability of a major osteoporosis-related fracture is ≥20 percent. When an osteoclast inhibitor is indicated, for most men, we suggest denosumab (60 mg subcutaneously every six months) rather than a bisphosphonate. The optimal duration is not known. For most men, we continue an osteoclast inhibitor for up to 36 months.
        </p>
        <p>
         Osteoclast inhibitors (either bisphosphonates or
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         ) are recommended for males with advanced prostate cancer and bone metastases to reduce the risk of a skeletal-related event [
         <a href="#rid13">
          13,22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/17128.html" rel="external">
          "Bone metastases in advanced prostate cancer: Management", section on 'Osteoclast inhibitors'
         </a>
         .)
        </p>
        <p>
         Osteoclast inhibitors can also decrease bone turnover and increase bone mineral density in males without bone metastases who are treated with long-term ADT and are at risk for bone fracture. There is no consensus on the optimal way to define males who are at elevated risk of fracture, and guidance from expert groups is variable (see
         <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">
          "Screening for osteoporosis in postmenopausal women and men", section on 'Fracture risk assessment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Our approach is consistent with guidelines from ASCO [
         <a href="#rid12">
          12,13
         </a>
         ], Cancer Care Ontario (CCO) [
         <a href="#rid22">
          22
         </a>
         ], and the NCCN [
         <a href="#rid11">
          11
         </a>
         ]. Estimates of fracture risk using the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sheffield.ac.uk%2FFRAX%2F&amp;token=FWNID0ZRoEvvwjKjY4KwHRcJtKEvPJpqM2LM0KvUOZmbLheqeTtnW9T2nrw6ABgh&amp;TOPIC_ID=6927" target="_blank">
          FRAX algorithm
         </a>
         , or the Canadian Association of Radiologists and Osteoporosis Canada tool [
         <a href="#rid23">
          23
         </a>
         ], and periodic bone density measurements may provide guidance when considering the use of an osteoclast inhibitor to prevent fracture, although none of these tools have been validated in patients with secondary osteoporosis caused by hormonal deprivation therapies [
         <a href="#rid17">
          17
         </a>
         ]. These guidelines all suggest the addition of an osteoclast inhibitor to reduce the risk of fracture in the setting of osteoporosis (T scores of -2.5 or less in the femoral neck, total hip, or lumbar spine) or when the estimated 10-year probability of hip fracture is ≥3 percent or the 10-year probability of a major osteoporosis-related fracture is ≥20 percent. However, the ASCO guidelines also state that the short-term bone loss associated with ADT can be rapid, and because of this, clinicians should consider treatment at a higher bone density or T score than is recommended using FRAX or similar tools, and males receiving ADT should be considered as having secondary osteoporosis in the FRAX assessment tool [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On the other hand, year 2021 guidelines on bone health from the European Society of Medical Oncology (ESMO) suggest the addition of a bone targeted agent for individuals with a T score less than -2, and for those with T score &gt;-2 and any two of the following risk factors [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age &gt;65
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         T score &lt;-1.5
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Smoking (current or past history)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Body mass index (BMI) &lt;24
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Family history of hip fracture
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Personal history of fragility fracture above age 50
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Oral glucocorticoid use for &gt;6 months
        </p>
        <p>
        </p>
        <p>
         When an osteoclast inhibitor is indicated, for most males with non-metastatic prostate cancer who are receiving ADT, we prefer
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         (60 mg subcutaneously every six months). Guidelines from CCO [
         <a href="#rid22">
          22
         </a>
         ], the National Osteoporosis Foundation [
         <a href="#rid25">
          25
         </a>
         ], the NCCN [
         <a href="#rid26">
          26
         </a>
         ], and ASCO [
         <a href="#rid12">
          12,13
         </a>
         ] all recommend that males who require drug therapy to prevent bone loss/fractures receive denosumab, an approved drug, at the dose and schedule recommended for prevention of osteoporosis (60 mg subcutaneously every six months). Bisphosphonates such as
         <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">
          zoledronic acid
         </a>
         are an alternative, but they are not approved specifically for prevention of bone loss/fractures in males receiving ADT. In this population, denosumab at this dose and schedule has been shown to reduce fractures, while other agents, including bisphosphonates, only improved bone mineral density [
         <a href="#rid27">
          27,28
         </a>
         ]. However, there is substantial indirect evidence for fracture reduction in other populations with osteoporosis with the use of bisphosphonates. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         .)
        </p>
        <p>
         Nevertheless, in situations or jurisdictions where
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         is contraindicated or not available, a bisphosphonate is a reasonable option [
         <a href="#rid13">
          13
         </a>
         ]. CCO guidelines suggest
         <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">
          zoledronic acid
         </a>
         at a dose of 5 mg by intravenous infusion once per year in this setting [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         The optimal duration of therapy with an osteoclast inhibitor is unknown. Current studies provide results up to 36 months of therapy [
         <a href="#rid13">
          13
         </a>
         ]. ESMO guidelines suggest continuation of the bone targeted agent for the duration of endocrine treatment or for up to five years.
        </p>
        <p>
         The risks and complications of osteoclast inhibitors are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2806.html" rel="external">
          "Risks of therapy with bone antiresorptive agents in patients with advanced malignancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96863.html" rel="external">
          "Medication-related osteonecrosis of the jaw in patients with cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h4">
          Denosumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          Denosumab
         </a>
         is a humanized monoclonal antibody that specifically binds to the receptor activator of nuclear factor kappa B ligand (RANKL), which is a key factor in osteoclast formation and function [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         The utility of
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         for the prevention of osteoporosis in males with non-metastatic, hormone-sensitive prostate cancer was demonstrated in a double-blind, trial in which 1468 males were randomly assigned to denosumab (60 mg subcutaneously every six months) or placebo [
         <a href="#rid29">
          29,30
         </a>
         ]. Overall, 912 patients (62 percent) completed the three year trial.
        </p>
        <p>
         All subjects had undergone bilateral orchiectomy or were receiving a gonadotropin-releasing hormone (GnRH) agonist on enrollment and were expected to remain on the GnRH agonist for at least 12 months. Patients were either ≥70 years old, or if &lt;70 years, had a low mineral density (T score less than -1 at the lumbar spine, hip, or femoral neck). Patients receiving treatment with bisphosphonates were excluded.
        </p>
        <p>
         Key results included the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At 36 months,
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         significantly increased bone density at all measured sites (lumbar spine, hip, femoral neck, and distal third of radius) compared with placebo. For the primary endpoint of the study, the bone mineral density in the lumbar spine, the increase with denosumab was 5.6 percent, compared with a decrease of 1 percent with placebo. The increase in bone density was progressive over the course of time at all sites and was statistically significant beginning one month after the start of treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment with
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         resulted in a statistically significant decrease in the incidence of new vertebral fractures at 12 and 36 months (cumulative incidence 0.3 versus 1.9 and 1.5 versus 3.9 percent, respectively). The incidence of fracture at any site was also decreased, although the difference was not statistically significant (5.2 versus 7.2 percent, relative risk 0.72, 95% CI 0.48-1.07).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The overall rate of adverse events was approximately 87 percent in both the
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         and placebo arms, with approximately equal rates of drop-out due to side effects (6.7 versus 6.5 percent). Cataracts developed more frequently in patients treated with denosumab (4.7 versus 1.2 percent), although these were not attributed to the study drug. Serious adverse events were slightly more common with denosumab (35 versus 31 percent). Deaths possibly related to treatment were observed in three patients treated with denosumab and four treated with placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metastasis to bone was diagnosed in three patients (0.4 percent) treated with
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         and ten (1.4 percent) treated with placebo.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H755483045">
         <span class="h4">
          Bisphosphonates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple small randomized trials have demonstrated that bisphosphonates can prevent the decrease in bone density associated with ADT [
         <a href="#rid31">
          31-35
         </a>
         ]. As an example, in one trial,
         <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">
          zoledronic acid
         </a>
         (4 mg every three months for one year) was compared with placebo in 106 males initiating ADT for non-metastatic prostate cancer [
         <a href="#rid32">
          32
         </a>
         ]. At one year, mean bone mineral density in the lumbar spine increased by an average of 5.6 percent in males receiving zoledronic acid, while it decreased by an average of 2.2 percent in those given placebo. For most men, we prefer zoledronic acid if a bisphosphonate is chosen over
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         . Although there is uncertainty as to the optimal frequency and duration of therapy, CCO guidelines (which have been endorsed by ASCO [
         <a href="#rid13">
          13
         </a>
         ]) suggest the use of 5 mg intravenously once every 12 months [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         In settings where intravenous
         <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">
          zoledronic acid
         </a>
         is unavailable, oral
         <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">
          alendronate
         </a>
         may be an acceptable alternative [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
         The risks and complications of long-term bisphosphonate use are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2806.html" rel="external">
          "Risks of therapy with bone antiresorptive agents in patients with advanced malignancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H342670399">
         <span class="h1">
          FALLS AND FRACTURES WITH ANDROGEN RECEPTOR INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Second generation antiandrogens (androgen receptor inhibitors [ARIs]) may be added to conventional ADT in males with metastatic or non-metastatic castration-resistant prostate cancer (
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">
          apalutamide
         </a>
         , or
         <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">
          darolutamide
         </a>
         ) and for advanced castration-sensitive prostate cancer (enzalutamide, apalutamide). (See
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway"
         </a>
         .)
        </p>
        <p>
         All three ARIs have been associated with an increased risk for falls and fractures. The best data come from a meta-analysis of eleven trials that included a total of 6536 males treated with
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">
          apalutamide
         </a>
         , or
         <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">
          darolutamide
         </a>
         in combination with ADT or other enzalutamide combinations for metastatic or non-metastatic, castration-resistant or castration-sensitive advanced prostate cancer, and 4846 males in the control group, who could have received placebo plus ADT,
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          bicalutamide
         </a>
         (a first generation androgen receptor inhibitor), or
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         [
         <a href="#rid36">
          36
         </a>
         ]. Use of an ARI was associated with a significantly increased risk for falls (risk ratio [RR] for all-grade falls 1.8, 95% CI 1.42-2.24) and fractures (RR for all-grade fractures 1.59, 95% CI 1.35-1.89). Both falls and fractures were most frequent with apalutamide (12 percent risk for falls and 10 percent risk for fracture).
        </p>
        <p>
         Data on the use of osteoclast inhibitors were not available for all studies, and the authors could not conclude whether use of one of these agents might have reduced the fracture rate. The reason(s) for the higher rate of falls with ARI could also not be discerned. Possible explanations include the ability of some these drugs to cross the blood-brain barrier (
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">
          apalutamide
         </a>
         ), treatment-induced sarcopenia or fatigue, and/or the use of concomitant medications or other predisposing conditions.
        </p>
        <p>
         Although the risk is overall low, clinicians might consider incorporating a fall-risk screening tool in older active males who are initiating an ARI for advanced prostate cancer  (
         <a class="graphic graphic_algorithm graphicRef69682" href="/z/d/graphic/69682.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3012.html" rel="external">
          "Falls in older persons: Risk factors and patient evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3014.html" rel="external">
          "Falls: Prevention in community-dwelling older persons"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          VASOMOTOR SYMPTOMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best treatment for hot flashes in males undergoing ADT is unclear. Megestrol and estrogen appear substantially more effective than
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         . However, the side effects differ between these agents (estrogen - breast symptoms, megestrol - increased appetite and weight, venlafaxine - dry mouth). We typically start with a selective serotonin reuptake inhibitor and reserve hormonal treatment (estrogen, megestrol) for refractory cases.
        </p>
        <p>
         The majority of males who receive ADT for prostate cancer experience hot flashes, including up to 80 percent of those receiving gonadotropin-releasing hormone (GnRH) agonists. Hot flashes affect quality of life, particularly if there are associated sleep problems.
        </p>
        <p>
         Hot flashes are usually described as an intense sensation of warmth in the face and upper part of the body. They may be associated with nausea and sweating, and may occur during sleep. Assessment should include duration, frequency, accompanying emotional or physical symptoms, and the degree of associated sleep disturbance.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Numerous approaches have been explored, similar to those used in postmenopausal females [
         <a href="#rid37">
          37
         </a>
         ]. However, at least one trial has suggested that agents that are effective in females may not be active in males who are androgen deprived [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7390.html" rel="external">
          "Menopausal hot flashes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The success of various agents for treatment of vasomotor symptoms in males ranges widely, and benefits must often be balanced against treatment-related side effects. The available evidence suggests that the pharmacologic approach to the management of hot flashes in males being treated with ADT is similar to that in women. (See
         <a class="medical medical_review" href="/z/d/html/7390.html" rel="external">
          "Menopausal hot flashes"
         </a>
         .)
        </p>
        <p>
         Potentially effective agents that have been evaluated in randomized trials include serotonin reuptake inhibitors, progestational agents, cyproterone, selective serotonin uptake inhibitors, and
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         [
         <a href="#rid39">
          39-41
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most extensive data on the treatment of hot flashes in males come from a trial in 311 males who had been treated with a GnRH agonist for six months and either were requesting treatment for hot flashes or had a minimum of 14 hot flashes per week [
         <a href="#rid39">
          39
         </a>
         ]. The males were randomly assigned to medroxyprogesterone (20 mg/day), cyproterone (100 mg/day), or the serotonin uptake inhibitor
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         (75 mg/day). Symptoms were reassessed at 4, 8, and 12 weeks after therapy initiation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         All three regimens significantly reduced hot flashes compared with baseline, but medroxyprogesterone and
         <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">
          cyproterone acetate
         </a>
         were significantly more effective than
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         (84 and 95 versus 47 percent reductions in symptom scores one month after starting treatment).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although
         <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">
          megestrol acetate
         </a>
         can successfully treat vasomotor symptoms, it should be used with caution as its use has been reported to cause rapid progression of prostate cancer [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
         was evaluated in a phase III trial in which 223 males who had at least 14 bothersome hot flashes per week while receiving ADT were randomly assigned to gabapentin at doses of 300, 600, or 900 mg daily or placebo [
         <a href="#rid40">
          40
         </a>
         ]. Gabapentin 900 mg daily was well tolerated and associated with a significant reduction in the frequency and intensity of hot flashes compared with placebo (46 versus 22 and 44 versus 27 percent reductions, respectively, at week 4 compared with baseline).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">
          Oxybutynin
         </a>
         has been shown to be beneficial for females with menopausal hot flashes [
         <a href="#rid44">
          44
         </a>
         ]. While randomized trials are not available, there is anecdotal experience supporting a potential benefit for oxybutynin in males receiving ADT [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7390.html" rel="external">
          "Menopausal hot flashes", section on 'Nonhormonal pharmacotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Alternative strategies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alternative or complementary therapies are increasingly popular as "natural remedies" for males who have side effects of ADT:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acupuncture may have some activity in ameliorating vasomotor symptoms due to ADT [
         <a href="#rid46">
          46-48
         </a>
         ]. In a small phase II study, 60 consecutive males receiving a GnRH analog were treated with acupuncture to the ear lobe; of these, 95 percent reported a significant decrease in the severity of symptoms [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Soy products,
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          vitamin E
         </a>
         , and herbal remedies have also been used with variable success in females with hot flashes. However, in a randomized, placebo controlled trial in 120 males with prostate cancer who were being managed with androgen deprivation neither soy protein nor
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         was more effective than placebo, which also significantly reduced the frequency and severity of hot flashes [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The lack of large, well organized prospective double-blind placebo-controlled trials makes it difficult to determine the true efficacy of any of these approaches.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          BODY COMPOSITION AND METABOLISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Males who are receiving ADT as well as those receiving androgen receptor pathway inhibitors (ARPIs) for prostate cancer should be encouraged to maintain a moderate exercise regimen. Greater intensity of screening for new onset diabetes and elevated cholesterol may also be appropriate. (See
         <a class="local">
          'Role of structured exercise'
         </a>
         below.)
        </p>
        <p>
         Treatment with ADT causes loss of lean body mass, increased body fat, decreased muscle strength, and decreased insulin sensitivity, all of which are probably due to reduced testosterone levels.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gonadotropin-releasing hormone (GnRH) agonists significantly decrease lean body mass (sarcopenia) and increase fat mass [
         <a href="#rid49">
          49,50
         </a>
         ]. Most of the fat accumulation is subcutaneous adipose tissue [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The decrease in lean body mass and increase in fat mass appear to begin within the first year, although some further decrease in muscle mass may be seen for at least three years [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Males being managed with ADT have a statistically significant increase in newly diagnosed (incident) diabetes [
         <a href="#rid53">
          53-56
         </a>
         ]. Further support for a causal relationship between ADT and diabetes comes from an analysis of 2237 propensity matched pairs of males with prevalent diabetes at the diagnosis of prostate cancer [
         <a href="#rid57">
          57
         </a>
         ]. Males who were treated with ADT had statistically significant increases in their use of diabetes pharmacotherapy and in their hemoglobin A1c levels at one and two years after initiation of ADT.
        </p>
        <p>
        </p>
        <p>
         Treatment-related changes in body composition are accompanied by important metabolic changes including reduced insulin sensitivity [
         <a href="#rid58">
          58,59
         </a>
         ] and increases in serum LDL-cholesterol, HDL-cholesterol, and triglycerides [
         <a href="#rid51">
          51,59-61
         </a>
         ]. These changes may also be seen with bilateral surgical orchiectomy [
         <a href="#rid62">
          62
         </a>
         ]. The US Food and Drug Administration (FDA) has issued a class labeling for GnRH agonists indicating that treatment may produce hyperglycemia and an increased risk of developing diabetes; insufficient data exist to conclude a similar risk in males treated with GnRH antagonists.
        </p>
        <p>
         Long-term use of newer forms of hormonal therapy such as ARPIs, including
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         ,
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">
          apalutamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">
          darolutamide
         </a>
         , are also associated with metabolic changes including an increased risk of diabetes [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          POTENTIAL CARDIOVASCULAR HARM
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common noncancer-related cause of death among prostate cancer survivors is cardiovascular disease (CVD) [
         <a href="#rid63">
          63
         </a>
         ]. There are conflicting results regarding the impact of long-term ADT on CVD risk, but none of the trials (until recently) were designed to specifically answer that question. However, taken together, the majority of studies, mainly observational, suggest that ADT increases cardiovascular morbidity and/or mortality, especially in those with pre-existing CVD. These risks are sufficient to support counseling and risk reduction measures for males initiating ADT [
         <a href="#rid5">
          5,64
         </a>
         ]. The potential benefits for males in whom long-term ADT is being considered as part of the management of their prostate cancer should always be balanced against any potential harm from ADT.
        </p>
        <p class="headingAnchor" id="H821008623">
         <span class="h2">
          Cardiac disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are conflicting results regarding the impact of long-term ADT on various cardiac parameters, with the majority of studies suggesting that ADT increases cardiovascular morbidity and/or mortality [
         <a href="#rid55">
          55,65-69
         </a>
         ], but a few failing to identify a statistically significant effect [
         <a href="#rid53">
          53,54
         </a>
         ]. An increased risk may be more evident in males who have had two or more prior CVD events, especially in the first six months after initiation of ADT [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         No placebo-controlled randomized trials have prospectively addressed the risks of CVD associated with conventional ADT, but retrospective data are available from both randomized trials and large observational series:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis incorporated data from 4141 patients who were enrolled on eight multicenter randomized phase III trials of injectable gonadotropin-releasing hormone (GnRH) agonists with median follow-ups ranging from 8 to 13 years [
         <a href="#rid71">
          71
         </a>
         ]. The incidence of cardiovascular death was not significantly different in those assigned to ADT compared with placebo (11 versus 11.2 percent, relative risk 0.93, p = 0.41). There was no increase in risk of cardiovascular death in those who received ADT for a short (six months or less) or long (three years or more) duration. Furthermore, the meta-analysis found that in 11 trials with 4805 patients, both the prostate cancer specific mortality and all-cause mortality were significantly
         <strong>
          lower
         </strong>
         in those assigned to ADT compared with placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On the other hand, in a second meta-analysis on observational data from eight large studies that included approximately 415,000 males managed with any form of ADT (GnRH agonist, orchiectomy, oral antiandrogens), the relative risk for males treated with a GnRH and any type of CVD was 1.38 (95% CI 1.29-1.48) [
         <a href="#rid72">
          72
         </a>
         ]. An increased risk of similar magnitude was observed for orchiectomy and antiandrogens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An increased risk of cardiovascular toxicity, particularly in males with pre-existing CVD, has also been seen with androgen synthesis inhibitors and androgen receptor antagonists, including
         <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">
          abiraterone
         </a>
         ,
         <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">
          enzalutamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">
          darolutamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">
          apalutamide
         </a>
         [
         <a href="#rid1">
          1,73,74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16351.html" rel="external">
          "Castration-resistant prostate cancer: Treatments targeting the androgen pathway"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14235.html" rel="external">
          "Overview of approach to prostate cancer survivors", section on 'Side effects of novel hormonal therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2690399698">
         <span class="h3">
          GnRH antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         A particular area of uncertainty is the relative cardiovascular toxicity of GnRH antagonists versus agonists. GnRH agonists (eg,
         <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">
          leuprolide
         </a>
         ) are by far the most commonly used form of medical castration while GnRH antagonists (
         <a class="drug drug_general" data-topicid="9073" href="/z/d/drug information/9073.html" rel="external">
          degarelix
         </a>
         , and the oral agent
         <a class="drug drug_general" data-topicid="130388" href="/z/d/drug information/130388.html" rel="external">
          relugolix
         </a>
         ) are used infrequently despite the fact that some data suggest that there may be less cardiovascular toxicity with GnRH antagonists as compared with agonists, making these agents particularly attractive for use in those with preexisting CVD. However, the choice of a GnRH agonist or antagonist may not be as important if aggressive risk-reduction cardiology care is provided to males with known CVD who are about to start ADT. (see
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer", section on 'GnRH antagonists'
         </a>
         )
        </p>
        <p>
         The available data are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pooled analysis from six phase III, prospective, randomized trials that recruited 2328 males receiving ADT (injectable GnRH agonists or GnRH antagonist
         <a class="drug drug_general" data-topicid="9073" href="/z/d/drug information/9073.html" rel="external">
          degarelix
         </a>
         ) concluded that the risk of cardiac events among males with pre-existing CVD within one year of initiating therapy was significantly lower in patients treated with a GnRH antagonist compared with a GnRH agonist (hazard ratio [HR] 0.44, 95% CI 0.26-0.74; p = 0.002) [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A similar conclusion was reached in the phase III HERO study, which randomly assigned 934 males with advanced prostate cancer to the investigational oral GnRH antagonist
         <a class="drug drug_general" data-topicid="130388" href="/z/d/drug information/130388.html" rel="external">
          relugolix
         </a>
         or to an injectable GnRH agonist [
         <a href="#rid76">
          76
         </a>
         ]. The primary endpoint was sustained testosterone suppression to castrate levels, and all other endpoints, including cardiovascular toxicity, were secondary. After 48 weeks of treatment, the incidence of major cardiovascular events was 54 percent lower with relugolix (2.9 versus 6.2 percent, HR 0.46, 95% CI 0.24-0.88), and the difference was even more marked in the subgroup of males with a history of cardiovascular events (3 of 84, 3.6 percent, versus 8 of 45, 17.8 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A later study reported that
         <a class="drug drug_general" data-topicid="9073" href="/z/d/drug information/9073.html" rel="external">
          degarelix
         </a>
         was associated with a lower cardiovascular risk than
         <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">
          leuprolide
         </a>
         [
         <a href="#rid77">
          77
         </a>
         ], but emphasized that none of the relevant trials addressing this issue was designed with cardiovascular morbidity as a primary endpoint.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On the other hand, the long-term relationship between ADT and cardiovascular risk, and potential differences between GnRH agonists versus antagonists were directly addressed in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02663908%3Fterm%3DPRONOUNCE%26cond%3DProstate%2BCancer%26draw%3D2%26rank%3D2&amp;token=LZk%2Fc44ECUImq1d4fWbb8SZS5novfPUFsVkpbx8ILnOTtoyimQc0i4NhsqF%2Bb2sOvaXIREkxVrj8nXt8NDrJcNj4WRak9SSy0NA%2BO0g39znVzesAI4PQyNQYpqzx5Udt4cXkOwyaNNpWEWOpHDUJdA%3D%3D&amp;TOPIC_ID=6927" target="_blank">
          PRONOUNCE trial
         </a>
         , a phase III trial of males with pre-existing CVD, which compared adjudicated major adverse cardiac events after
         <a class="drug drug_general" data-topicid="9073" href="/z/d/drug information/9073.html" rel="external">
          degarelix
         </a>
         or
         <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">
          leuprolide
         </a>
         [
         <a href="#rid78">
          78
         </a>
         ]. The study failed to show a lower cardiovascular risk profile with degarelix compared with leuprolide. Notably, all patients on the study were required to have their cardiac care optimized by a cardiologist prior to and during the trial, and this may have resulted in the lower rates of observed versus anticipated cardiovascular events in the leuprolide arm.
        </p>
        <p>
        </p>
        <p>
         These disparate results have led some to conclude that the potential for lower cardiovascular risk cannot solely justify the use of GnRH antagonists in prostate cancer patients who have preexisting CVD [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         The potential benefits of ADT when used for appropriate indications in prostate cancer must always be weighed against the potential risks of toxicity, especially of cardiovascular events. A simple screening tool called STAMP identifies males at highest risk of CVD by asking if the patient has had a diagnosis of
         <strong>
          S
         </strong>
         troke;
         <strong>
          T
         </strong>
         ransient ischemic attack;
         <strong>
          A
         </strong>
         bdominal aortic aneurysm or other aortic disease;
         <strong>
          M
         </strong>
         yocardial infarction, angina, or previous revascularization; or
         <strong>
          P
         </strong>
         eripheral vascular disease [
         <a href="#rid80">
          80
         </a>
         ]. If an individual has any of these conditions, they should be considered at risk for an adverse cardiovascular event during ADT.
        </p>
        <p class="headingAnchor" id="H1605226906">
         <span class="h2">
          Thromboembolic events
         </span>
         <span class="headingEndMark">
          —
         </span>
         Males with prostate cancer who are treated with ADT appear to be at increased risk of thromboembolic events (deep venous thrombosis, pulmonary embolus, arterial embolism).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis that analyzed data from 10 studies including more than 250,000 individuals found that the use of ADT was associated with an increased risk of thromboembolic events (risk ratio [RR] 1.43, 95% CI 1.15-1.77) [
         <a href="#rid81">
          81
         </a>
         ]. In those studies in which the use of ADT was limited to patients with localized prostate cancer, there was also a significant increase (RR 1.10, 95% CI 1.05-1.16).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, in a Surveillance, Epidemiology, and End Results (SEER) database study that included approximately 155,000 men, 38 percent of whom received ADT, there was a significantly increased risk of thromboembolic events compared with those not on ADT (15 versus 7 percent, HR 1.56) [
         <a href="#rid82">
          82
         </a>
         ]. A Swedish study that included approximately 77,000 males with prostate cancer found that the risk of thromboembolic events was increased in all males with prostate cancer, and that the risk was greatest in those who were treated with endocrine therapy [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H553595385">
         <span class="h2">
          Risk reduction strategies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Males starting on ADT, especially those at high risk, should be followed and managed by a multidisciplinary team and treated according to best practices including [
         <a href="#rid80">
          80
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If lipids are abnormal, use statin therapy to lower low-density lipoprotein cholesterol. (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease", section on 'Indications for statin therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If blood pressure exceeds goal based on cardiovascular risk, add antihypertensive therapy. (See
         <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">
          "Goal blood pressure in adults with hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If fasting glucose is elevated and hemoglobin A1c is abnormal, approaches to lowering glucose are appropriate. (See
         <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">
          "Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'Diagnostic tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with known CVD should take
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (generally 81 mg/day) unless contraindicated. (See
         <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">
          "Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Males who continue to smoke should be referred to smoking cessation programs. (See
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Identify patients who might benefit from referral to a cardio-oncology clinic (eg, myocardial dysfunction, atrial fibrillation, uncontrolled hypertension or diabetes [
         <a href="#rid84">
          84
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H147147743">
         <span class="h1">
          KIDNEY INJURY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two large studies observed an association between treatment with ADT and an increased risk of acute kidney injury [
         <a href="#rid85">
          85-87
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective, nested case control analysis, 232 cases of acute kidney injury were observed in 10,250 males with newly diagnosed, non-metastatic prostate cancer diagnosed between 1997 and 2008 for an incidence of 5.5 cases per 1000 patient years [
         <a href="#rid85">
          85
         </a>
         ]. These cases were matched with 2721 controls with attention to identifiable risk factors. Overall, the current use of ADT was associated with an increased risk of acute kidney injury compared with those who had never used ADT (odds ratio 2.48, 95% CI 1.61-3.82). When cases were analyzed based upon the type of ADT, most of the excess risk was related to combination regimens that included a gonadotropin-releasing hormone (GnRH) agonists and an antiandrogen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study from the Surveillance, Epidemiology, and End Results (SEER) database identified 69,292 males diagnosed with non-metastatic prostate cancer between 1995 and 2009 [
         <a href="#rid86">
          86
         </a>
         ]. The 10-year rate of acute kidney injury was significantly elevated in males treated with ADT compared with those who were ADT naïve (30.7 versus 24.9 percent, p &lt;0.001). These differences were predominantly seen in males treated with GnRH agonists (31.1 versus 26 percent, p &lt;0.001), and the differences were not significant in those managed with orchiectomy.
        </p>
        <p>
        </p>
        <p>
         However, it is unclear whether these observations represent a causal relationship between ADT with a GnRH agonist and acute kidney injury and additional studies are required. A number of confounding factors that could not be controlled for, such as the use of bisphosphonates or the progression of underlying prostate cancer, may account for these observed differences [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          FATIGUE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fatigue or lack of energy is a highly prevalent and often annoying side effect of ADT. In one study, fatigue was severe in 14 percent of males after only three months of therapy [
         <a href="#rid88">
          88
         </a>
         ]. The extent of fatigue does not seem to correlate with anemia or emotional cognitive issues.
        </p>
        <p>
         Regular exercise appears to be beneficial in ameliorating the fatigue associated with ADT [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="local">
          'Role of structured exercise'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2802.html" rel="external">
          "Cancer-related fatigue: Prevalence, screening, and clinical assessment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2813.html" rel="external">
          "Cancer-related fatigue: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          ANEMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia develops in up to 90 percent of males receiving long-term ADT [
         <a href="#rid5">
          5
         </a>
         ]. It is usually mild to moderate, normochromic, and normocytic [
         <a href="#rid90">
          90-93
         </a>
         ]. The relationship between anemia and fatigue symptoms is unclear [
         <a href="#rid92">
          92,93
         </a>
         ].
        </p>
        <p>
         Anecdotal evidence suggests that the anemia associated with ADT is highly responsive to erythropoietin (EPO) therapy. However, EPO is rarely necessary, and we reserve it for symptomatic patients.
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          ISSUES RELATED TO BODY IMAGE
         </span>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Gynecomastia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gynecomastia is caused by an increased ratio of estrogen to androgen activity. Gynecomastia is common in males with prostate cancer undergoing ADT, and it is particularly prevalent with antiandrogen monotherapy. Gynecomastia causes significant alterations in body image and is often associated with breast tenderness as well [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Drug therapy (
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         ) and prophylactic radiation therapy (RT) are effective in most cases when initiated prior to the development of gynecomastia. However, both approaches have limited benefit once gynecomastia is established. (See
         <a class="medical medical_review" href="/z/d/html/7467.html" rel="external">
          "Management of gynecomastia", section on 'Men with prostate cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H252483799">
         <span class="h2">
          Weight gain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Self-image is central to self-confidence and sexual performance. The prevalence of obesity (BMI &gt;30 kg/m
         <sup>
          2
         </sup>
         ) at the time of diagnosis was 26 percent in one study [
         <a href="#rid94">
          94
         </a>
         ], and obesity after diagnosis of prostate cancer is associated with higher cardiovascular and all-cause mortality [
         <a href="#rid95">
          95
         </a>
         ]. While obesity in males with newly diagnosed prostate cancer has usually developed over many years, up to 70 percent of males gain an average of 10 pounds within one year of starting ADT [
         <a href="#rid96">
          96
         </a>
         ]. The weight gain is typically due to an increase in body fat in the waist, hips, and thighs, resulting in a feminizing effect. Many males report increased hunger and more snacking between meals. In order to minimize weight gain or achieve weight loss, referral to a dietician is suggested at initiation of ADT to review healthy eating habits and snacking strategies. The importance of adequate exercise in addition to dietary changes is discussed in detail below. (See
         <a class="local">
          'Role of structured exercise'
         </a>
         below.).
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Decreased penile and testicular size
         </span>
         <span class="headingEndMark">
          —
         </span>
         A decrease in the size of the penis and/or testicles is a common side effect of ADT, which may be distressing to the patient [
         <a href="#rid5">
          5,97,98
         </a>
         ]. Males should be warned of this potential complication; there are no treatments to mitigate this side effect.
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h2">
          Thinning of body hair
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thinning of body hair is another unexpected and disconcerting side effect that should be discussed with the patient before therapy is started. Although facial and most body hair are decreased, bald males may regrow some scalp hair [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          EMOTIONAL AND COGNITIVE CHANGES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Circulating testosterone levels have behavioral and neurologic effects in humans, and both testosterone concentration and neurocognitive function decrease with aging in normal men.
        </p>
        <p>
         There is some evidence to suggest a link between ADT and neurocognitive dysfunction, including Alzheimer disease and other forms of dementia; however, it is inconsistent and nonspecific. At least some data support the view that advanced age, comorbidity, and advanced disease stage may account for much of the cognitive disorders seen in these men, and that cognitive dysfunction may have preceded the diagnosis of prostate cancer [
         <a href="#rid100">
          100-106
         </a>
         ]. As an example, in an analysis of 1.2 million Medicare beneficiaries treated for prostate cancer over a 14-year period, 9 percent were diagnosed with Alzheimer disease, and 19 percent developed dementia [
         <a href="#rid102">
          102
         </a>
         ]. There was a slight increase in the unadjusted risk of both Alzheimer disease and dementia among males receiving ADT. However, after adjusting for cancer therapy and other variables, there was no increased risk of Alzheimer disease (hazard ratio [HR] 0.98) and only a trivial increased risk of dementia (HR 1.01). No ADT dose effect on Alzheimer disease or dementia was noted (less than one year versus longer).
        </p>
        <p>
         On the other hand, others note an elevated risk for dementia even after adjusting for factors such as age and comorbidity:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a population-based cohort study of 154,089 older adult males diagnosed with prostate cancer between 1996 and 2003 derived from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, 62,330 received ADT within two years of diagnosis, while 91,759 did not [
         <a href="#rid105">
          105
         </a>
         ]. At a mean follow-up of 8.3 years, exposure to ADT was associated with a diagnosis of Alzheimer disease (13.1 versus 9.4 percent; HR 1.56, 95% CI 1.51-1.60) and dementia (21.6 versus 15.8 percent, HR 1.61. 95% CI 1.57-1.65), and risk was still significantly elevated after adjustment for age at diagnosis, race/ethnicity, geographic area, marital status, comorbidity score, cancer stage, and socioeconomic status (propensity score-adjusted HR for Alzheimer disease 1.14 [95% CI 1.10-1.18] and risk for dementia 1.20 [95% CI 1.17-1.24]). Risk was higher for longer duration of ADT therapy (for &gt;8 doses, the propensity score-adjusted HR was 1.24 for Alzheimer disease [95% CI 1.16-1.34] and 1.21 [95% CI 1.15-1.28] for dementia); for one to four doses, the corresponding HRs were 1.19 (95% CI 1.15-1.24) for Alzheimer disease and 1.19 (95% CI 1.15-1.23) for dementia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of 14 studies of males with prostate cancer who did or did not receive ADT using a GnRH agonist or antagonist included nine studies reporting all-cause dementia, eight reporting Alzheimer disease, and five assessing outcomes according to the duration of ADT [
         <a href="#rid107">
          107
         </a>
         ]. The risk of new-onset dementia or Alzheimer disease saw modestly but significantly higher in males receiving ADT compared with those who did not (HR 1.21, 95% CI 1.11-1.33, and HR 1.16, 95% CI 1.09-1.24). When five studies were analyzed according to treatment duration, the elevated risk for all-cause dementia seemed limited to those who received ADT for longer than 12 months (HR 1.36, 95% CI 1.07-1.72), but not for shorter durations (HR 1.06, 95% CI 0.77-1.28). For Alzheimer disease, the higher magnitude of risk that was observed with longer duration therapy was not statistically significant (HR 1.39, 95% CI 0.69-2.79).
        </p>
        <p>
        </p>
        <p>
         Updated year 2019 guidelines for management of prostate cancer in older patients from the International Society of Geriatric Oncology (SIOP) suggest that clinicians discuss the risk of neurocognitive dysfunction with older patients with prostate cancer who are considering use of ADT [
         <a href="#rid108">
          108
         </a>
         ]. However, in our view, ADT clearly benefits males with metastatic hormone sensitive or locally advanced prostate cancer, and we do not consider that the risk of neurocognitive dysfunction, if it exists, should form the basis for refusing ADT in these settings. (See
         <a class="medical medical_review" href="/z/d/html/14257.html" rel="external">
          "Prostate cancer in older males"
         </a>
         .)
        </p>
        <p>
         Treatment with ADT has also been associated with an increased incidence of depression and anxiety. In a systematic review and meta-analysis that included results from 18 studies with 169,000 individuals, there was a 41 percent increase in the risk of depression [
         <a href="#rid109">
          109
         </a>
         ]. Anxiety was increased in an analysis of 79,000 males aged ≥66 years treated with ADT (three-year cumulative incidence 4.1 versus 3.5 percent) [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H339914843">
         <span class="h1">
          ROLE OF STRUCTURED EXERCISE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most men receiving ADT for prostate cancer, we suggest moderate exercise, to include three or more hours of aerobic activity weekly, plus resistance training and weight-bearing exercises.
        </p>
        <p>
         Structured exercise programs have been studied in a number of trials as a way to prevent or ameliorate ADT-related complications. Overall, there is good evidence that exercise can provide benefit for muscle mass and strength, cardiorespiratory fitness, fatigue and declining physical function, less robust evidence for exercise-induced improvements in bone loss, prevention of falls and fractures, sexual dysfunction, and anxiety and depression. The following data are available:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A systematic review analyzed the impact of various aerobic and/or resistance training programs in males being treated with ADT for prostate cancer in 10 studies that were published between 1980 and 2013 [
         <a href="#rid111">
          111
         </a>
         ]. The studies analyzed included five that were randomized trials and five that evaluated males pre- and postexercise program. Although the specific exercise interventions varied, exercise resulted in substantial improvements in muscular strength, cardiorespiratory fitness, functional task performance, lean body mass, and fatigue in males on ADT. (See
         <a class="medical medical_review" href="/z/d/html/2813.html" rel="external">
          "Cancer-related fatigue: Treatment", section on 'Exercise'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Resistance exercise training and high-impact loading exercises may also help to mitigate ADT-related bone loss, improving bone health, and reducing fracture risk, but the data are inconsistent [
         <a href="#rid112">
          112
         </a>
         ]. While two systematic reviews and meta-analyses of the most effective method for preventing osteoporosis in males receiving ADT for prostate cancer concluded that exercise alone was insufficient to address bone loss [
         <a href="#rid113">
          113,114
         </a>
         ], improvements in, or preservation of bone mineral density for males with prostate cancer receiving ADT who participated in an exercise intervention (endurance training, resistance exercises, impact loading exercise) has been shown in at least three contemporary trials [
         <a href="#rid115">
          115-117
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence from one systematic review [
         <a href="#rid114">
          114
         </a>
         ] and one small randomized trial [
         <a href="#rid118">
          118
         </a>
         ] suggest that exercise can help to maintain or improve sexual health following prostate cancer treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least six systematic reviews have concluded that physical activity improves quality of life, including mental health domains [
         <a href="#rid111">
          111,119-124
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         There currently are inadequate data to define the optimal exercise regimen. In one analysis of 21 trials involving 1748 patients with prostate cancer, structured resistance-based exercise improved fat mass, lean mass, and fitness outcomes including muscle strength with no change in body mass index or PSA [
         <a href="#rid125">
          125
         </a>
         ]. Meta-regression indicated no association between exercise type, duration, weekly volume or intensity on any of the primary outcomes. There was an association between exercise intensity and chest press muscle strength favoring moderate intensity, but not in other endpoints.
        </p>
        <p>
         These data are consistent with published guidelines, which generally endorse moderate exercise for individuals with cancer [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1072375233">
         <span class="h1">
          ALTERNATIVE HORMONE STRATEGIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the side effects associated with ADT and their impact on quality of life, alternative hormone strategies such as antiandrogen monotherapy or intermittent ADT may occasionally be required to minimize these problems. However, the potential benefit from the use of these approaches should not be allowed to compromise disease control.
        </p>
        <p class="headingAnchor" id="H1072375019">
         <span class="h2">
          Antiandrogen monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antiandrogen monotherapy has been advocated as an alternative to ADT as a way to avoid some of the side effects associated with medical or surgical castration, but this approach is not considered an accepted alternative in current management guidelines. In two small randomized trials, the antiandrogen
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          bicalutamide
         </a>
         increased bone density at multiple sites, while medical castration with a gonadotropin-releasing hormone (GnRH) agonist was associated with a decrease in bone density [
         <a href="#rid127">
          127,128
         </a>
         ].
        </p>
        <p>
         However, the use of antiandrogen monotherapy appears to be associated with a decrease in antitumor efficacy in multiple randomized clinical trials when compared with medical castration. A meta-analysis that included 2717 patients found a trend toward shorter overall survival with antiandrogen monotherapy compared with castration that approached, but did not reach, statistical significance (hazard ratio [HR] 1.22, 95% CI 0.99-1.40) [
         <a href="#rid129">
          129
         </a>
         ]. Antiandrogen monotherapy may be a reasonable option for carefully selected males with well-differentiated tumors and a prostate-specific antigen (PSA)-only recurrence who wish to minimize side effects during therapy. (See
         <a class="medical medical_review" href="/z/d/html/6933.html" rel="external">
          "Role of systemic therapy in patients with a biochemical recurrence after treatment for localized prostate cancer", section on 'Continuous versus intermittent ADT'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1072375025">
         <span class="h2">
          Intermittent androgen deprivation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intermittent androgen deprivation (IAD) refers to cyclic administration of GnRH agonists with temporary withdrawal of therapy once a response has been achieved. Treatment is then reinitiated when there is evidence of progression.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For males with metastatic disease, a phase III trial found that IAD could not be considered noninferior compared with continuous ADT in terms of overall survival [
         <a href="#rid130">
          130
         </a>
         ]. However, a preliminary analysis of quality of life suggested an improvement in sexual functioning; additional analyses are ongoing [
         <a href="#rid131">
          131
         </a>
         ]. Based upon the available evidence, IAD cannot be recommended in this setting. (See
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer", section on 'Intermittent versus continuous ADT'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For males whose only evidence of disseminated disease is an elevated serum PSA, a phase III trial found that males treated with IAD had more disease-related deaths but fewer unrelated deaths compared with continuous ADT [
         <a href="#rid132">
          132
         </a>
         ]. Patients treated with IAD had a reduced frequency of hot flashes, but there were no other differences in adverse events. IAD cannot be routinely recommended and patients must be fully counseled that there are limited data to support a benefit for this approach. (See
         <a class="medical medical_review" href="/z/d/html/6933.html" rel="external">
          "Role of systemic therapy in patients with a biochemical recurrence after treatment for localized prostate cancer", section on 'Continuous versus intermittent ADT'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Androgen deprivation therapy (ADT) is the main therapeutic approach for males with metastatic prostate cancer and is frequently used in combination with other treatments (including androgen synthesis inhibitors and androgen receptor antagonists) in selected patients with locoregional disease. (See
         <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">
          "Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sexual dysfunction
         </strong>
         – Most males who are potent prior to therapy develop sexual dysfunction when treated with continuous ADT. While not inevitable, loss of libido develops in most males receiving gonadotropin releasing hormone (GnRH) agonists, usually within the first several months, and erectile dysfunction typically follows. (See
         <a class="local">
          'Sexual dysfunction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osteoporosis and risk of bone fractures
         </strong>
         – ADT increases bone turnover and decreases bone mineral density, thereby increasing the risk of clinical bone fractures. (See
         <a class="local">
          'Osteoporosis and bone fractures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For all males beginning long-term ADT, we recommend dietary calcium intake (food and supplements) of 1000 to 1200 mg daily and supplemental vitamin D 800 to 1000 international units daily, as well as weight bearing exercise, decreased alcohol consumption, and smoking cessation. (See
         <a class="local">
          'Preventive strategies'
         </a>
         above and
         <a class="local">
          'Role of structured exercise'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In males without bone metastases who are treated with long-term ADT, an osteoclast inhibitor such as a bisphosphonate or
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         can decrease bone turnover and increase bone mineral density. An osteoclast inhibitor may be offered to reduce the risk of fracture in the setting of osteoporosis (T scores of -2.5 or less in the femoral neck, total hip, or lumbar spine), or when the 10-year probability of hip fracture (using the FRAX algorithm or a different tool) is ≥3 percent or the 10-year probability of a major osteoporosis-related fracture is ≥20 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         When an osteoclast inhibitor is indicated, for most men, we suggest
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         (60 mg subcutaneously every six months) rather than a bisphosphonate (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Osteoclast inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The optimal duration is not known. For most men, we continue an osteoclast inhibitor for up to 36 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular disease and diabetes
         </strong>
         – The most common noncancer-related cause of death among prostate cancer survivors is cardiovascular disease (CVD). There are conflicting results regarding the impact of long-term ADT on CVD risk, but few trials were designed to specifically answer that question. However, taken together, the majority of studies, mainly observational, suggest that ADT, as well as other forms of hormone therapy such as androgen synthesis inhibitors and androgen receptor antagonists, increase cardiovascular morbidity and/or mortality, especially in those with pre-existing CVD. These risks are sufficient to support counseling and risk reduction measures for males initiating ADT. The potential benefits for males in whom long-term ADT is being considered as part of the management of their prostate cancer should always be balanced against any potential harm from adverse cardiovascular events. (See
         <a class="local">
          'Potential cardiovascular harm'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Decreased muscle and increased fat
         </strong>
         – Reduced testosterone levels associated with ADT result in a decrease in lean body mass and an increase in subcutaneous adipose tissue. Most of these changes occur during the first 18 months of treatment. (See
         <a class="local">
          'Body composition and metabolism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cognitive dysfunction
         </strong>
         – A growing body of evidence supports a link between ADT and cognitive dysfunction, including Alzheimer disease and other forms of dementia, although the data are inconsistent. Nevertheless, updated year 2019 guidelines from the International Society of Geriatric Oncology (SIOP) suggest that clinicians discuss the risk of cognitive dysfunction with older males with prostate cancer who are considering the use of ADT. (See
         <a class="local">
          'Emotional and cognitive changes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other quality of life issues
         </strong>
         – ADT may result in a number of other changes that can adversely affect quality of life. These include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hot flashes. The optimal management of vasomotor symptoms is unclear. We typically start with a selective serotonin reuptake inhibitor or
         <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">
          oxybutynin
         </a>
         and reserve hormonal treatment (estrogen, megestrol) for refractory cases. (See
         <a class="local">
          'Vasomotor symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lack of energy, which may only partially be related to anemia or emotional and cognitive issues. (See
         <a class="local">
          'Fatigue'
         </a>
         above and
         <a class="local">
          'Anemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Changes in body image, including gynecomastia, decreased penile and testicular size, and thinning of body hair. (See
         <a class="local">
          'Issues related to body image'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Decreased cognitive performance or depression, although these changes may be related to aging and disease rather than ADT. (See
         <a class="local">
          'Emotional and cognitive changes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of exercise
         </strong>
         – For most males, we suggest three or more hours of aerobic activity weekly in conjunction with resistance training and weight bearing exercises. (See
         <a class="local">
          'Role of structured exercise'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2403466708">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges E David Crawford, MD, who contributed to an earlier version of this topic review.
        </p>
        <p>
         We are saddened by the death of Nicholas Vogelzang, MD, who passed away in September 2022. UpToDate gratefully acknowledges Dr. Vogelzang's role as Section Editor on this topic, and his dedicated and longstanding involvement with the UpToDate program.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lai LY, Oerline MK, Caram MEV, et al. Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer. J Natl Cancer Inst 2022; 114:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating NL. Cardiovascular and Metabolic Diagnoses Associated With Novel Hormonal Agents for Prostate Cancer in Nontrial Populations. J Natl Cancer Inst 2022; 114:1057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gay HA, Sanda MG, Liu J, et al. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. Int J Radiat Oncol Biol Phys 2017; 98:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fode M, Sønksen J. Sexual Function in Elderly Men Receiving Androgen Deprivation Therapy (ADT). Sex Med Rev 2014; 2:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23:7897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saad F, Adachi JD, Brown JP, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008; 26:5465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krupski TL, Smith MR, Lee WC, et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004; 101:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154.
          </a>
         </li>
         <li class="breakAll">
          NCCN guidelines available online at https://www.nccn.org/professionals/physician_gls/ (Accessed on December 02, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. J Clin Oncol 2019; 37:2916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saylor PJ, Rumble RB, Tagawa S, et al. Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. J Clin Oncol 2020; 38:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown JE, Handforth C, Compston JE, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol 2020; 25:100311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suarez-Almazor ME, Pundole X, Cabanillas G, et al. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer. JAMA Netw Open 2022; 5:e225432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan S, Wagner J, Resnick NM, et al. Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer. J Clin Densitom 2011; 14:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalla Volta A, Mazziotti G, Maffezzoni F, et al. Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies. J Clin Oncol 2020; 38:3363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003; 21:1653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002; 167:1952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bae DC, Stein BS. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol 2004; 172:2137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 2004; 46:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alibhai SMH, Zukotynski K, Walker-Dilks C, et al. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline. Clin Oncol (R Coll Radiol) 2017; 29:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182:1864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2020; 31:1650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 2014; 25:2359.
          </a>
         </li>
         <li class="breakAll">
          NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on April 12, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alibhai SMH, Zukotynski K, Walker-Dilks C, et al. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. Ann Intern Med 2017; 167:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyashita H, Satoi S, Cruz C, et al. Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis. Support Care Cancer 2022; 30:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009; 182:2670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169:2008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klotz LH, McNeill IY, Kebabdjian M, et al. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur Urol 2013; 63:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choo R, Lukka H, Cheung P, et al. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2013; 85:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myint ZW, Momo HD, Otto DE, et al. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis. JAMA Netw Open 2020; 3:e2025826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frisk J. Managing hot flushes in men after prostate cancer--a systematic review. Maturitas 2010; 65:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitolins MZ, Griffin L, Tomlinson WV, et al. Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. J Clin Oncol 2013; 31:4092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irani J, Salomon L, Oba R, et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010; 11:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loprinzi CL, Dueck AC, Khoyratty BS, et al. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 2009; 20:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999; 162:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sartor O, Eastham JA. Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. South Med J 1999; 92:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tassinari D, Fochessati F, Panzini I, et al. Rapid progression of advanced "hormone-resistant" prostate cancer during palliative treatment with progestins for cancer cachexia. J Pain Symptom Manage 2003; 25:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon JA, Gaines T, LaGuardia KD, Extended-Release Oxybutynin Therapy for VMS Study Group. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause 2016; 23:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith TJ, Loprinzi CL, Deville C. Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men. N Engl J Med 2018; 378:1745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harding C, Harris A, Chadwick D. Auricular acupuncture: a novel treatment for vasomotor symptoms associated with luteinizing-hormone releasing hormone agonist treatment for prostate cancer. BJU Int 2009; 103:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beer TM, Benavides M, Emmons SL, et al. Acupuncture for hot flashes in patients with prostate cancer. Urology 2010; 76:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashamalla H, Jiang ML, Guirguis A, et al. Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy. Int J Radiat Oncol Biol Phys 2011; 79:1358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alibhai SM, Breunis H, Timilshina N, et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 2010; 28:5038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Saad F, Egerdie B, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol 2012; 30:3271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008; 71:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27:3452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24:4448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai HT, Keating NL, Van Den Eeden SK, et al. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol 2015; 193:1956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating NL, Liu PH, O'Malley AJ, et al. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014; 65:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24:3979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braga-Basaria M, Muller DC, Carducci MA, et al. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 2006; 18:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yannucci J, Manola J, Garnick MB, et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006; 176:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reis C, Liberman S, Pompeo AC, et al. Body composition alterarions, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy. Clinics (Sao Paulo) 2009; 64:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc 2009; 57:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okwuosa TM, Morgans A, Rhee JW, et al. Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association. Circ Genom Precis Med 2021; 14:e000082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99:1516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009; 302:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crawford ED, Moul JW. ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. Oncology (Williston Park) 2015; 29:55.
          </a>
         </li>
         <li class="breakAll">
          Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer J Am Coll Cardiol CardioOnc 2020; 2:553. Article available online at https://www.jacc.org/doi/10.1016/j.jaccao.2020.08.011 (Accessed on December 07, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Farrell S, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2015; 33:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306:2359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 2015; 68:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iacovelli R, Ciccarese C, Bria E, et al. The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. Clin Genitourin Cancer 2018; 16:e645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higano CS. Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer. N Engl J Med 2020; 382:2257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014; 65:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shore ND, Saad F, Cookson MS, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020; 382:2187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallach JD, Deng Y, McCoy RG, et al. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Netw Open 2021; 4:e2130587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopes RD, Higano CS, Slovin SF, et al. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation 2021; 144:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tisseverasinghe S, Tolba M, Saad F, et al. Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists? J Clin Oncol 2022; 40:4173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenk M, Grégoire JC, Coté MA, et al. Optimizing screening and management of cardiovascular health in prostate cancer: A review. Can Urol Assoc J 2020; 14:E458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nead KT, Boldbaatar N, Yang DD, et al. Association of Androgen Deprivation Therapy and Thromboembolic Events: A Systematic Review and Meta-analysis. Urology 2018; 114:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehdaie B, Atoria CL, Gupta A, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer 2012; 118:3397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Hemelrijck M, Adolfsson J, Garmo H, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol 2010; 11:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin E, Garmo H, Van Hemelrijck M, et al. Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes. JAMA Netw Open 2022; 5:e2225600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapi F, Azoulay L, Niazi MT, et al. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA 2013; 310:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gandaglia G, Sun M, Hu JC, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol 2014; 66:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR. Androgen deprivation therapy and acute kidney injury. JAMA 2013; 310:2313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone P, Hardy J, Huddart R, et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taaffe DR, Newton RU, Spry N, et al. Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial. Eur Urol 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beer TM, Tangen CM, Bland LB, et al. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894. Cancer 2006; 107:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 2006; 176:2443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strum SB, McDermed JE, Scholz MC, et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997; 79:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choo R, Chander S, Danjoux C, et al. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? Can J Urol 2005; 12:2547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agalliu I, Williams S, Adler B, et al. The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics. Cancer Causes Control 2015; 26:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Troeschel AN, Hartman TJ, Jacobs EJ, et al. Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer. J Clin Oncol 2020; 38:2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braunstein LZ, Chen MH, Loffredo M, et al. Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. Prostate Cancer 2014; 2014:230812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haliloglu A, Baltaci S, Yaman O. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer. J Urol 2007; 177:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park KK, Lee SH, Chung BH. The effects of long-term androgen deprivation therapy on penile length in patients with prostate cancer: a single-center, prospective, open-label, observational study. J Sex Med 2011; 8:3214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higano C. Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin North Am 2006; 20:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nead KT, Gaskin G, Chester C, et al. Association Between Androgen Deprivation Therapy and Risk of Dementia. JAMA Oncol 2017; 3:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khosrow-Khavar F, Rej S, Yin H, et al. Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer. J Clin Oncol 2017; 35:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baik SH, Kury FSP, McDonald CJ. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer. J Clin Oncol 2017; 35:3401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nead KT, Sinha S, Nguyen PL. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2017; 20:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun M, Cole AP, Hanna N, et al. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol 2018; 199:1417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayadevappa R, Chhatre S, Malkowicz SB, et al. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer. JAMA Netw Open 2019; 2:e196562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           R Buskbjerg C, Zachariae R, Buus S, et al. Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in patients with newly diagnosed prostate cancer referred to androgen-deprivation therapy. Cancer 2021; 127:1495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sari Motlagh R, Quhal F, Mori K, et al. The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol 2021; 205:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyle HJ, Alibhai S, Decoster L, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 2019; 116:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nead KT, Sinha S, Yang DD, Nguyen PL. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis. Urol Oncol 2017; 35:664.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinh KT, Yang DD, Nead KT, et al. Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. Int J Urol 2017; 24:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 2014; 32:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edmunds K, Tuffaha H, Scuffham P, et al. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review. Support Care Cancer 2020; 28:5661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph JS, Lam V, Patel MI. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Eur Urol Oncol 2019; 2:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yunfeng G, Weiyang H, Xueyang H, et al. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis. Medicine (Baltimore) 2017; 96:e7368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taaffe DR, Galvão DA, Spry N, et al. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition. BJU Int 2019; 123:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uth J, Hornstrup T, Schmidt JF, et al. Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy. Scand J Med Sci Sports 2014; 24 Suppl 1:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newton RU, Galvão DA, Spry N, et al. Exercise Mode Specificity for Preserving Spine and Hip Bone Mineral Density in Prostate Cancer Patients. Med Sci Sports Exerc 2019; 51:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cormie P, Newton RU, Taaffe DR, et al. Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial. Prostate Cancer Prostatic Dis 2013; 16:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourke L, Smith D, Steed L, et al. Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016; 69:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chipperfield K, Brooker J, Fletcher J, Burney S. The impact of physical activity on psychosocial outcomes in men receiving androgen deprivation therapy for prostate cancer: a systematic review. Health Psychol 2014; 33:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourke L, Boorjian SA, Briganti A, et al. Survivorship and improving quality of life in men with prostate cancer. Eur Urol 2015; 68:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baguley BJ, Bolam KA, Wright ORL, Skinner TL. The Effect of Nutrition Therapy and Exercise on Cancer-Related Fatigue and Quality of Life in Men with Prostate Cancer: A Systematic Review. Nutrients 2017; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vashistha V, Singh B, Kaur S, et al. The Effects of Exercise on Fatigue, Quality of Life, and Psychological Function for Men with Prostate Cancer: Systematic Review and Meta-analyses. Eur Urol Focus 2016; 2:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rendeiro JA, Rodrigues CAMP, de Barros Rocha L, et al. Physical exercise and quality of life in patients with prostate cancer: systematic review and meta-analysis. Support Care Cancer 2021; 29:4911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez P, Taaffe DR, Newton RU, Galvão DA. Resistance Exercise Dosage in Men with Prostate Cancer: Systematic Review, Meta-analysis, and Meta-regression. Med Sci Sports Exerc 2021; 53:459.
          </a>
         </li>
         <li class="breakAll">
          CANCER CARE ONTARIO GUIDELINES. Available at: https://www.exerciseismedicine.org/canada/support_page.php/cancer-care-ontario-guidelines1/ (Accessed on February 05, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MR, Goode M, Zietman AL, et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004; 22:2546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieber PR, Keiller DL, Kahnoski RJ, et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171:2272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussain M, Tangen CM, Higano CS, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. J Clin Oncol 2012; 30S: ASCO #4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moinpour C, Berry DL, Ely B, et al. Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)—Phase III. J Clin Oncol 2012; 30S: ASCO #4571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klotz L, O'Callaghan CJ, Ding K, et al. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG  JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol 2011; 29S: ASCO #3.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6927 Version 71.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35417024" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35417007" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cardiovascular and Metabolic Diagnoses Associated With Novel Hormonal Agents for Prostate Cancer in Nontrial Populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28463150" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27784542" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Sexual Function in Elderly Men Receiving Androgen Deprivation Therapy (ADT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25097095" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Adverse effects of androgen deprivation therapy and strategies to mitigate them.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16258089" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18955443" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cancer treatment-induced bone loss in breast and prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9781950" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15274067" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15647578" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Risk of fracture after androgen deprivation for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15647578" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Risk of fracture after androgen deprivation for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31532726" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31990618" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32995252" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35363269" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21723763" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32603244" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12721238" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11956415" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15538219" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15548440" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28169118" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20940232" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32801018" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Bone health in cancer: ESMO Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25182228" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinician's Guide to Prevention and Treatment of Osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25182228" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clinician's Guide to Prevention and Treatment of Osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28785760" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34392414" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19671656" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19836774" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11575286" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12771706" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17371886" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23040208" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23265571" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33201234" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19962840" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Managing hot flushes in men after prostate cancer--a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24081940" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19963436" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19129205" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10379749" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10219363" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12727047" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Rapid progression of advanced "hormone-resistant" prostate cancer during palliative treatment with progestins for cancer cachexia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27760081" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29719180" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18710455" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Auricular acupuncture: a novel treatment for vasomotor symptoms associated with luteinizing-hormone releasing hormone agonist treatment for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20494414" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Acupuncture for hot flashes in patients with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20605360" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21041715" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22649143" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Sarcopenia during androgen-deprivation therapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11836291" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Changes in body composition during androgen deprivation therapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18308111" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19506162" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16983113" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19996060" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25524243" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23453420" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16434464" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Insulin sensitivity during combined androgen blockade for prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16921050" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16617314" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16813881" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19722072" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Body composition alterarions, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19054189" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cause of death in older men after the diagnosis of prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33896190" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17657815" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17925537" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19706860" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25592210" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25592210" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25732167" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22147380" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25484142" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29339044" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32469186" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24210090" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32469183" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34677594" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34459214" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35862876" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32569573" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Optimizing screening and management of cardiovascular health in prostate cancer: A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29352986" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Association of Androgen Deprivation Therapy and Thromboembolic Events: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22072494" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Androgen deprivation and thromboembolic events in men with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20395174" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35939302" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23860987" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24495466" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24302098" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Androgen deprivation therapy and acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10854947" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Fatigue in patients with prostate cancer receiving hormone therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28249801" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16804926" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17085125" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9202563" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15777493" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25771797" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32250715" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24864213" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17162022" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21699669" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : The effects of long-term androgen deprivation therapy on penile length in patients with prostate cancer: a single-center, prospective, open-label, observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16861122" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Androgen deprivation therapy: monitoring and managing the complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27737437" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Association Between Androgen Deprivation Therapy and Risk of Dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27870566" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28841388" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28349979" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29410294" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31268539" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33351221" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in patients with newly diagnosed prostate cancer referred to androgen-deprivation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32856962" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31195356" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28803700" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28734019" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24344218" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32699997" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31411986" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28682886" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30239116" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24944134" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30395051" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Exercise Mode Specificity for Preserving Spine and Hip Bone Mineral Density in Prostate Cancer Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23318529" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26632144" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24245841" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : The impact of physical activity on psychosocial outcomes in men receiving androgen deprivation therapy for prostate cancer: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25941049" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Survivorship and improving quality of life in men with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28895922" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : The Effect of Nutrition Therapy and Exercise on Cancer-Related Fatigue and Quality of Life in Men with Prostate Cancer: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28723375" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : The Effects of Exercise on Fatigue, Quality of Life, and Psychological Function for Men with Prostate Cancer: Systematic Review and Meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33649920" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Physical exercise and quality of life in patients with prostate cancer: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32890199" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Resistance Exercise Dosage in Men with Prostate Cancer: Systematic Review, Meta-analysis, and Meta-regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32890199" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Resistance Exercise Dosage in Men with Prostate Cancer: Systematic Review, Meta-analysis, and Meta-regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15226323" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15126801" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10744594" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)—Phase III
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG  JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
